RxSight (NASDAQ:RXST) Releases Earnings Results, Beats Expectations By $0.06 EPS

RxSight (NASDAQ:RXST) issued its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06, Briefing.com reports. RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. During the same quarter last year, the firm earned ($0.40) EPS. RxSight’s quarterly revenue was up 67.6% on a year-over-year basis.

RxSight Stock Up 1.2 %

NASDAQ:RXST traded up $0.59 during trading hours on Wednesday, reaching $48.44. 56,054 shares of the stock were exchanged, compared to its average volume of 487,565. The stock has a market capitalization of $1.79 billion, a P/E ratio of -37.98 and a beta of 1.19. RxSight has a 52 week low of $20.66 and a 52 week high of $66.54. The firm has a 50 day simple moving average of $53.18 and a 200-day simple moving average of $53.45.

Insider Buying and Selling

In related news, insider Ilya Goldshleger sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.25, for a total value of $353,250.00. Following the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,658,155.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Ilya Goldshleger sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.25, for a total value of $353,250.00. Following the sale, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,658,155.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Julie Andrews sold 15,625 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $58.00, for a total value of $906,250.00. Following the completion of the sale, the director now directly owns 30,287 shares in the company, valued at approximately $1,756,646. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,625 shares of company stock valued at $1,845,600. Insiders own 9.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Stifel Nicolaus lowered their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday. Wells Fargo & Company lowered their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday. Needham & Company LLC lowered their price objective on RxSight from $75.00 to $54.00 and set a “buy” rating for the company in a research note on Tuesday. BTIG Research increased their target price on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Oppenheimer reduced their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $58.43.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.